blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP2935278

EP2935278 - TRICYCLIC COMPOUNDS FOR INHIBITING THE CFTR CHANNEL [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  19.01.2018
Database last updated on 25.09.2024
FormerThe patent has been granted
Status updated on  10.02.2017
FormerGrant of patent is intended
Status updated on  03.11.2016
Most recent event   Tooltip17.07.2020Lapse of the patent in a contracting state
New state(s): AL		published on 19.08.2020  [2020/34]
Applicant(s)For all designated states
Novartis AG
Lichtstrasse 35
4056 Basel / CH
[2015/44]
Inventor(s)01 / AHMED, Mahbub
Srg
5th Floor
5 Devonshire Square
London EC2M 4YD / GB
02 / ASHALL-KELLY, Alexander
Srg
5th Floor
5 Devonshire Square
London EC2M 4YD / GB
03 / GUERITZ, Louisa
Srg
5th Floor
5 Devonshire Square
London EC2M 4YD / GB
04 / MCKENNA, Jeffrey
Novartis Pharmaceuticals UK Limited
Wimblehurst Road
Horsham Sussex RH12 5AB / GB
05 / MCKENNA, Joseph
Srg
5th Floor
5 Devonshire Square
London EC2M 4YD / GB
06 / MUTTON, Simon
Srg
5th Floor
5 Devonshire Square
London EC2M 4YD / GB
07 / PARMAR, Rakesh
Srg
5th Floor
5 Devonshire Square
London EC2M 4YD / GB
08 / SHEPHERD, Jon
Srg
5th Floor
5 Devonshire Square
London EC2M 4YD / GB
09 / WRIGHT, Paul
Srg
5th Floor
5 Devonshire Square
London EC2M 4YD / GB
 [2015/44]
Representative(s)Dyer, James
Novartis Pharma AG
Patent Department
4002 Basel / CH
[2015/44]
Application number, filing date13826625.917.12.2013
[2015/44]
WO2013IB61043
Priority number, dateUS201261739335P19.12.2012         Original published format: US 201261739335 P
US201361906141P19.11.2013         Original published format: US 201361906141 P
[2015/44]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2014097148
Date:26.06.2014
Language:EN
[2014/26]
Type: A1 Application with search report 
No.:EP2935278
Date:28.10.2015
Language:EN
The application published by WIPO in one of the EPO official languages on 26.06.2014 takes the place of the publication of the European patent application.
[2015/44]
Type: B1 Patent specification 
No.:EP2935278
Date:15.03.2017
Language:EN
[2017/11]
Search report(s)International search report - published on:EP26.06.2014
ClassificationIPC:C07D487/14, C07D487/04, C07D495/14, A61K31/519, A61P13/12, A61P1/12
[2015/44]
CPC:
C07D513/14 (EP,US); A61K31/519 (EP,US); A61K31/542 (EP,US);
A61K31/55 (EP,US); A61K45/06 (US); A61P1/12 (EP);
A61P13/12 (EP); A61P43/00 (EP); C07D471/14 (EP,US);
C07D487/04 (EP,US); C07D487/14 (EP,US); C07D487/22 (EP,US);
C07D495/14 (EP,US); C07D513/00 (EP,US) (-)
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2015/44]
Extension statesBA20.07.2015
TitleGerman:TRICYCLISCHE VERBINDUNGEN ZUR HEMMUNG DES CFTR-KANALS[2015/44]
English:TRICYCLIC COMPOUNDS FOR INHIBITING THE CFTR CHANNEL[2015/44]
French:COMPOSÉS TRICYCLIQUES POUR INHIBER LE CANAL CFTR[2015/44]
Entry into regional phase20.07.2015National basic fee paid 
20.07.2015Designation fee(s) paid 
20.07.2015Examination fee paid 
Examination procedure20.07.2015Examination requested  [2015/44]
22.12.2015Amendment by applicant (claims and/or description)
30.05.2016Communication of intention to grant the patent
23.09.2016Disapproval of the communication of intention to grant the patent by the applicant or resumption of examination proceedings by the EPO
04.11.2016Communication of intention to grant the patent
31.01.2017Fee for grant paid
31.01.2017Fee for publishing/printing paid
31.01.2017Receipt of the translation of the claim(s)
Divisional application(s)The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is  30.05.2016
Opposition(s)18.12.2017No opposition filed within time limit [2018/08]
Fees paidRenewal fee
10.12.2015Renewal fee patent year 03
13.12.2016Renewal fee patent year 04
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipHU17.12.2013
AL15.03.2017
AT15.03.2017
CY15.03.2017
CZ15.03.2017
DK15.03.2017
EE15.03.2017
FI15.03.2017
HR15.03.2017
LT15.03.2017
LV15.03.2017
MC15.03.2017
MK15.03.2017
NL15.03.2017
PL15.03.2017
RO15.03.2017
RS15.03.2017
SE15.03.2017
SI15.03.2017
SK15.03.2017
SM15.03.2017
TR15.03.2017
BG15.06.2017
NO15.06.2017
GR16.06.2017
IS15.07.2017
PT17.07.2017
IE17.12.2017
LU17.12.2017
MT17.12.2017
[2020/34]
Former [2020/15]HU17.12.2013
AT15.03.2017
CY15.03.2017
CZ15.03.2017
DK15.03.2017
EE15.03.2017
FI15.03.2017
HR15.03.2017
LT15.03.2017
LV15.03.2017
MC15.03.2017
MK15.03.2017
NL15.03.2017
PL15.03.2017
RO15.03.2017
RS15.03.2017
SE15.03.2017
SI15.03.2017
SK15.03.2017
SM15.03.2017
TR15.03.2017
BG15.06.2017
NO15.06.2017
GR16.06.2017
IS15.07.2017
PT17.07.2017
IE17.12.2017
LU17.12.2017
MT17.12.2017
Former [2019/52]HU17.12.2013
AT15.03.2017
CY15.03.2017
CZ15.03.2017
DK15.03.2017
EE15.03.2017
FI15.03.2017
HR15.03.2017
LT15.03.2017
LV15.03.2017
MC15.03.2017
MK15.03.2017
NL15.03.2017
PL15.03.2017
RO15.03.2017
RS15.03.2017
SE15.03.2017
SI15.03.2017
SK15.03.2017
SM15.03.2017
BG15.06.2017
NO15.06.2017
GR16.06.2017
IS15.07.2017
PT17.07.2017
IE17.12.2017
LU17.12.2017
MT17.12.2017
Former [2019/47]HU17.12.2013
AT15.03.2017
CY15.03.2017
CZ15.03.2017
DK15.03.2017
EE15.03.2017
FI15.03.2017
HR15.03.2017
LT15.03.2017
LV15.03.2017
MC15.03.2017
NL15.03.2017
PL15.03.2017
RO15.03.2017
RS15.03.2017
SE15.03.2017
SI15.03.2017
SK15.03.2017
SM15.03.2017
BG15.06.2017
NO15.06.2017
GR16.06.2017
IS15.07.2017
PT17.07.2017
IE17.12.2017
LU17.12.2017
MT17.12.2017
Former [2019/31]HU17.12.2013
AT15.03.2017
CZ15.03.2017
DK15.03.2017
EE15.03.2017
FI15.03.2017
HR15.03.2017
LT15.03.2017
LV15.03.2017
MC15.03.2017
NL15.03.2017
PL15.03.2017
RO15.03.2017
RS15.03.2017
SE15.03.2017
SI15.03.2017
SK15.03.2017
SM15.03.2017
BG15.06.2017
NO15.06.2017
GR16.06.2017
IS15.07.2017
PT17.07.2017
IE17.12.2017
LU17.12.2017
MT17.12.2017
Former [2019/30]AT15.03.2017
CZ15.03.2017
DK15.03.2017
EE15.03.2017
FI15.03.2017
HR15.03.2017
LT15.03.2017
LV15.03.2017
MC15.03.2017
NL15.03.2017
PL15.03.2017
RO15.03.2017
RS15.03.2017
SE15.03.2017
SI15.03.2017
SK15.03.2017
SM15.03.2017
BG15.06.2017
NO15.06.2017
GR16.06.2017
IS15.07.2017
PT17.07.2017
IE17.12.2017
LU17.12.2017
MT17.12.2017
Former [2018/45]AT15.03.2017
CZ15.03.2017
DK15.03.2017
EE15.03.2017
FI15.03.2017
HR15.03.2017
LT15.03.2017
LV15.03.2017
NL15.03.2017
PL15.03.2017
RO15.03.2017
RS15.03.2017
SE15.03.2017
SI15.03.2017
SK15.03.2017
SM15.03.2017
BG15.06.2017
NO15.06.2017
GR16.06.2017
IS15.07.2017
PT17.07.2017
IE17.12.2017
LU17.12.2017
MT17.12.2017
Former [2018/43]AT15.03.2017
CZ15.03.2017
DK15.03.2017
EE15.03.2017
FI15.03.2017
HR15.03.2017
LT15.03.2017
LV15.03.2017
NL15.03.2017
PL15.03.2017
RO15.03.2017
RS15.03.2017
SE15.03.2017
SI15.03.2017
SK15.03.2017
SM15.03.2017
BG15.06.2017
NO15.06.2017
GR16.06.2017
IS15.07.2017
PT17.07.2017
LU17.12.2017
MT17.12.2017
Former [2018/14]AT15.03.2017
CZ15.03.2017
DK15.03.2017
EE15.03.2017
FI15.03.2017
HR15.03.2017
LT15.03.2017
LV15.03.2017
NL15.03.2017
PL15.03.2017
RO15.03.2017
RS15.03.2017
SE15.03.2017
SI15.03.2017
SK15.03.2017
SM15.03.2017
BG15.06.2017
NO15.06.2017
GR16.06.2017
IS15.07.2017
PT17.07.2017
Former [2018/09]AT15.03.2017
CZ15.03.2017
DK15.03.2017
EE15.03.2017
FI15.03.2017
HR15.03.2017
LT15.03.2017
LV15.03.2017
NL15.03.2017
PL15.03.2017
RO15.03.2017
RS15.03.2017
SE15.03.2017
SK15.03.2017
SM15.03.2017
BG15.06.2017
NO15.06.2017
GR16.06.2017
IS15.07.2017
PT17.07.2017
Former [2017/51]AT15.03.2017
CZ15.03.2017
EE15.03.2017
FI15.03.2017
HR15.03.2017
LT15.03.2017
LV15.03.2017
NL15.03.2017
PL15.03.2017
RO15.03.2017
RS15.03.2017
SE15.03.2017
SK15.03.2017
SM15.03.2017
BG15.06.2017
NO15.06.2017
GR16.06.2017
IS15.07.2017
PT17.07.2017
Former [2017/50]AT15.03.2017
CZ15.03.2017
EE15.03.2017
FI15.03.2017
HR15.03.2017
LT15.03.2017
LV15.03.2017
NL15.03.2017
PL15.03.2017
RO15.03.2017
RS15.03.2017
SE15.03.2017
SK15.03.2017
BG15.06.2017
NO15.06.2017
GR16.06.2017
IS15.07.2017
Former [2017/49]AT15.03.2017
CZ15.03.2017
EE15.03.2017
FI15.03.2017
HR15.03.2017
LT15.03.2017
LV15.03.2017
NL15.03.2017
RO15.03.2017
RS15.03.2017
SE15.03.2017
SK15.03.2017
BG15.06.2017
NO15.06.2017
GR16.06.2017
IS15.07.2017
Former [2017/48]CZ15.03.2017
FI15.03.2017
HR15.03.2017
LT15.03.2017
LV15.03.2017
NL15.03.2017
RS15.03.2017
SE15.03.2017
BG15.06.2017
NO15.06.2017
GR16.06.2017
Former [2017/41]FI15.03.2017
HR15.03.2017
LT15.03.2017
LV15.03.2017
NL15.03.2017
RS15.03.2017
SE15.03.2017
BG15.06.2017
NO15.06.2017
GR16.06.2017
Cited inInternational search[A]WO2012166658  (UNIV CALIFORNIA [US], et al) [A] 1-17 * page 4, line 26 - page 5, line 10 ** claims 1, 7 *
by applicantWO2004078163
    - SHEPPARD ET AL., PHYSIOL. REV., (1999), vol. 79, pages 23 - 45
    - GADSBY ET AL., NATURE, (2006), vol. 40, pages 477 - 83
    - THIAGARAJAH; VERKMAN, CLINICAL PHARMACOLOGY AND THERAPEUTICS, (2012), vol. 92, no. 3, pages 287 - 290
    - Remington's Pharmaceutical Sciences, MACK PRINTING COMPANY, (1990), pages 1289 - 1329
    - QUINTON, PHYSIOL. REV., (1999), vol. 79, pages S3 - S22
    - BOUCHER, EUR. RESPIR. J, (2004), vol. 23, pages 146 - 58
    - O'SULLIVAN ET AL., AM. J KIDNEY DIS., (1998), vol. 32, pages 976 - 983
    - SULLIVAN ET AL., PHYSIOL. REV., (1998), vol. 78, pages 1165 - 91
    - STRONG ET AL., J CLIN. INVEST., (1994), vol. 93, pages 347 - 54
    - MALL ET AL., GASTROENTEROLOGY, (2004), vol. 126, pages 32 - 41
    - HANAOKA ET AL., AM. J PHYSIOL., (1996), vol. 270, pages C389 - C399
    - KUNZELMANN ET AL., PHYSIOL. REV., (2002), vol. 82, pages 245 - 289
    - DAVIDOW ET AL., KIDNEY INT., (1996), vol. 50, pages 208 - 18
    - LI ET AL., KIDNEY INT., (2004), vol. 66, pages 1926 - 38
    - AI-AWQATI, J CLIN. INVEST., (2002), vol. 110, pages 1599 - 1601
    - THIAGARAJAH ET AL., CURR. OPIN. PHARMACOL., (2003), vol. 3, pages 594 - 99
    - CLARK ET AL., SCIENCE, (1992), vol. 257, pages 1125 - 28
    - GABRIEL ET AL., SCIENCE, (1994), vol. 266, pages 107 - 109
    - KUNZELMANN; MALL, PHYSIOL. REV., (2002), vol. 82, pages 245 - 89
    - FIELD, M., J CLIN. INVEST., (2003), vol. 111, pages 931 - 43
    - THIAGARAJAH ET AL., GASTROENTEROLOGY, (2003), vol. 126, pages 511 - 519
    - HAMILL 0; MARTY A; NEHER E; SAKMANN B; SIGWORTH F., "Improved patch-clamp techniques for high resolution current recording from cells and cell-free membrane patches", PFLUGERS ARCHIVE, (1981), vol. 391, doi:doi:10.1007/BF00656997, pages 85 - 100, XP000196663

DOI:   http://dx.doi.org/10.1007/BF00656997
    - FINKEL A; WITTEL A; YANG N; HANDRAN S; HUGHES J; COSTANTIN J., "Population patch clamp improves data consistency and success rates in the measurement of ionic currents", J BIOMOL SCREEN., (200608), vol. 11, no. 5, doi:doi:10.1177/1087057106288050, pages 488 - 96, XP008097818

DOI:   http://dx.doi.org/10.1177/1087057106288050
    - J.AM.CHEM.SOC., (1959), vol. 81, pages 2705 - 2715
    - TRUJILLO, D.A.; MCMAHON, W.A.; LYLE, R.E., "Synthesised by a modified Method of", J. ORG. CHEM., (1987), vol. 52, pages 2932 - 2933
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.